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Autologous transplantation in poor risk Hodgkin's disease using high dose
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Newcastle and Northern Region Lymphoma Group*
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Centre, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne, UK.
Summary This study aimed to assess the safety and efficacy of using high dose melphalan and etoposide
followed by autologous, non-cryopreserved marrow rescue in advanced Hodgkin's disease (HD).
Seventeen patients with poor risk Hodgkin's disease from a single centre underwent autologous bone
marrow transplant (ABMT) using high dose melphalan and etopside conditioning. Two patients had primary
progressive resistant disease (PD), two were in fourth relapse, six in second or third complete remission (CR),
one patient had good partial response (GPR) (>75% reduction in initial bulk) to primary therapy and six
were in first complete remission. The patients transplanted in first CR all has a Scotland and Newcastle
Lymphoma Group (SNLG) Prognostic Index (Proctor et al., 1991) which indicated they were in a poor risk
prognostic group. Melphalan and etoposide both have a short half life enabling ABMT to be accomplished
using unmanipulated marrow stored at 4'C. The marrow was returned to the patient within 56 h of harvest.
Complete haematological reconstitution occurred in 16/17 patients, the rate of engraftment reflecting the
amount of previous chemotherapy. One patient died of progressive Hodgkin's disease before full engraftment
could occur. In patients autografted in first remission, the median number of days with neutropenia
(<0.5 x 109 1' neutrophils) was 19 (range 9-33) and, in those in subsequent remission, 27 days (range
18-36). The median number of days to 50 x 109 1-l platelets in the same groups were 29 (21-80) and 50
(41-74) respectively. The number of days in hospital post transplant in both groups was similar; median 22
(15-27) and 23 (17-37) respectively.
There were no procedural deaths and none of the patients transplanted in first, second or third CR have
relapsed (median follow up 21 months). The two patients transplanted with progressive disease showed only
temporary reponses. The two patients transplanted in fourth relapse went into CR; one is still alive and in CR
15 months post transplant, but the other relapsed 18 months post transplant.
This form of intensification therapy with marrow rescue has been shown to be effective and of low toxicity
and now forms part of a randomised controlled trial in poor risk Hodgkin's patients as identified by the
SNLG index (Proctor et al., 1992).
Autologous bone marrow transplantation (ABMT) is used
increasingly in the treatment of lymphoid malignancies. Our
Group has used ABMT as part of intensification therapy in
acute lymphoblastic leukemia (ALL) in first CR since 1984
(Proctor et al., 1985; Proctor et al., 1988) and in poor
prognosis non-Hodgkin's lymphoma (NHL) in first CR since
1985 (Carey et al., 1991). The conditioning regimen used in
ALL and NHL has been melphalan alone (3mgkg-' body
weight) or melphalan (3 mg kg-' body weight) plus total
body irradiation (TBI) (1050 cGy in three fractions of 350
cGy). Marrow rescue has utilised non-cryopreserved, non-
purged marrow. We have found this to be a safe procedure
and details of the rate of haematopoietic reconstitution, lack
of toxicity and efficacy have been published elsewhere (Carey
et al., 1991). There has been no procedural mortality in the
groups of patients mentioned.
During 1986, we formulated a numerical prognostic index
with the intention of identifying at diagnosis those HD
patients destined to die of their disease. Such patients were to
be given alternative, more aggressive, first line treatment. The
index allowed us to separate poor prognosis patients from
those who would be cured with four drug CLVPP/MOPP
type regimens, thus avoiding over-treating this latter group
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(Proctor et al., 1991). This approach has now been modified
and refined by the addition of a factor for bulk disease
(Proctor et al., 1992) and the Scotland and Newcastle Lym-
phoma Group (SNLG) is undertaking a trial of ABMT
versus intensive conventional therapy in poor risk patients
(Proctor et al., 1992). The high dose intensification for this
trial was chosen, in part, as a result of data emerging from
the patients described in the present paper. The choice of
preconditioning for HD was based on our experience with
melphalan in high grade non-Hodgkin's lymphoma autot-
ransplants and the fact that it had been shown to have value
in other series of ABMT in HD (Russell et al., 1989; Zulian
et al., 1989). It was considered that VP16, known to be an
active agent in HD, used at high dose would be of benefit
(Zulian et al., 1989; Wolff et al., 1983; Blume et al., 1987;
Jagannath et al., 1986; Stewart et al., 1991). All agents for
this procedure needed a short half-life if our policy of using
non-cryopreserved marrow, which is associated with rapid
engraftment and lack of procedural mortality (Carey et al.,
1991), was to continue.
This study aimed to assess the toxicity of adding high dose
etoposide to melphalan as preconditioning for ABMT, and
to make a preliminary assessment of the efficacy of this drug
combination utilised early in poor risk cases. The results of
the first 17 patients treated are described here.
Patients and methods
Seventeen patients were enrolled in the study between August
1986 and August 1991. Follow-up is to the 31st December,
1991. There were eight females and nine males and the
median age was 28 years (range 19-46). Two patients had
primary resistant disease, two were in fourth relapse, six were
in second or subsequent complete remission and seven had
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ABMT following primary therapy, six in first CR and one in
maximal first response (GPR) (>75% reduction). The latter
seven patients were all judged poor risk by the SNLG prog-
nostic index (Table I) (Proctor et al., 1991; Proctor et al.,
1992). Details of all 17 patients are shown in Table II.
Histology showed 11/17 had nodular sclerosing Hodgkin's
disease; five mixed cellularity and one lymphocyte depleted.
Marrow harvest and conditioning
Bone marrow aspiration and trephine were performed one
month prior to transplant to confirm that the marrow was
disease free and adequately cellular. Bone marrow was
harvested by multiple needle aspirations from the posterior
iliac crests. Patients were given 2,000 IU sodium heparin IV
immediately pre-harvest and the marrow was placed in acid
citrate dextrose anticoagulant in standard blood transfusion
collection bags. It was then kept at 4°C for up to 56 h. The
cell dose aimed for was >2 x 108 kg-' and the median cell
dose given was 2.96 x 10 kg-1 (range 1.34-7.3). After mar-
row harvest, patients received etopside 1600 mg m2 as a
20 h infusion, followed by 3 mg kg-' of melphalan as a
15 min infusion. After a further 24 h, the harvested marrow
was returned to the patient, unmanipulated, through a stan-
dard blood giving set.
Post transplant care
Patients were managed in single rooms from the day of
transplant until their neutrophils were >0.5 x 1091', but
they were under no major restrictions and were allowed free
movement around the ward. Medical and nursing staff used
regular hand washing as the only specific precaution against
infection. Normal food was allowed and there was unrest-
ricted visiting by close relatives.
Bowel decontamination was achieved using non-absorbable
antibiotics (colistin and vancomycin) and prophylactic anti-
viral (acyclovir) and anti-fungal (nystatin and amphotericin)
therapy was given. All blood products were irradiated and
CMV -ve.
Multiple-donor platelet transfusions were given if platelets
were <20 x 1091- and red blood cell transfusions if Hb
<100 g-'. Fever > 380C was treated empirically with broad
spectrum antibiotics. Patient 5 received 5 itg kg-' of G-CSF
(Chugai) as part of a clinical trial.
Results
Haematologic reconstitution
Complete marrow re-engraftment occurred in 16 of the 17
patients. One patient died of progressive HD with partial
engraftment. The rate of reconstitution was most rapid in
those transplanted in first CR (Table III). The median
number of days <0.5 x 109 1' neutrophils and the days of
platelet support in patients having transplant in first CR were
less than those whose transplants were performed in subse-
quent CR. Those patients transplanted with active disease
had a still more prolonged period of neutropenia and throm-
bocytopenia.
Other toxicity
Mild/moderate oral mucositis occurred (WHO grade <2)
(World Health Organization, 1979) in all patients. Nausea
and vomiting during the etoposide infusion was effectively
controlled by the 5HT antagonist, ondansetron 8 mg IV
twice daily. Transient pyrexia was associated with the
etoposide infusion, but settled within 24 h, and did not
require medication routinely. Sixteen of the 17 patients
required antibiotics for pyrexial episodes (>38°C) during the
transplant admission. No significant renal or hepatic toxicity
was observed. No patients developed pneumonitis or
required intensive care management for pulmonary problems.
Patients transplanted in CR spent a median of 21 days (range
14-37) in hospital post transplant. Two patients (6 and 14)
spent an extra 10 and 7 days in hospital. This prolonged
hospitalisation was a condition of a drug trial. There were no
procedural deaths.
Effect on disease
All 12 patients transplanted in CR are alive and well and in
maintained CR a median of 21 months post transplant
(range 6-48). Patients 17, transplanted in GPR, who had
Table I Calculation of the Prognostic Index for Hodgkin's disease with bulk disease*
To calculate the index patient's age, clinical stage, absolute lymphocyte count, haemoglobin and
bulk disease are required.
The index (1) = 1.5858-0.0363 Age + 0.0005 (Age2)
+ 0.0683 CS-0.086 LC-0.0587 Hb
+ additional factor if bulk disease is present*
Age is entered as an absolute figure in the equation
Clinical stage entered according to the key (Ann Arbor Classification)
IA, hIA, IIIA
IB, IIB
IIIB
IV
=
=2
=3
=4
Absolute lymphocyte count is entered as a score
<1.0x1091-' =1
1.0-1.5x1091-' =2
1.5-2.0 x 1091-' = 3
>2.0x1091-' =4
Haemoglobin (Hb) in gdl-' is entered as an absolute figure in equation
*Bulk disease (>10 cm) or >30% of internal
thoracic diameter at D5-index score add 0.3
The equation looks complicated, but is easily entered on a computer or programmable
calculator. The index can then be generated for any patient within minutes. The major strength
is that with the exception of stage, which is a composite clinical parameter, all other data are
absolute values. Details for entry on IBM compatible computer available from first author.
Patients with index 0.5 have risk of death from progressive HD of 60-70% in 4 years. Such
patients are being entered on an autotransplant protocol in first remission.TREATMENT FOR ADVANCED HODGKIN'S DISEASE 385
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Table III Toxicity data
Autotransplant after
Autotransplant after 2nd/3rd complete
primary therapy remission
(Median and range) (Median and range)
Age 24 (19-38) 27 (21-33)
Days of platelet
transfusions 4 (3-20) 22 (4-29)
Days of
neutropenia* 19 (9-33) 27 (18-36)
Documented
infections 0 (0-2) 1 (1-3)
Units of packed
cells 3 (2-8) 6 (0-9)
Days in hospital
from day of 20 (15-27) 23 (14-37)
transplant
*Neutropenia is <0.5 x I0 1-' neutrophils in peripheral blood
residual mediastinal bulk, relapsed 15 months post trans-
plant, but following one course of oral PECC (prednisolone,
etoposide, chlorambucil and CCNU) (Lennard et al., 1990)
went into remission and remains in CR at 53 months post
transplant. Two patient with resistant disease were trans-
planted and both demonstrated a temporary partial response
(Table II). Two patients transplanted after fourth relapse
showed good response to ABMT; their transplants had been
perceived as salvage therapy; but both went into CR. One
patient remains in CR 15 months post transplant and the
other relapsed at 18 months.
Discussion
Ann Arbor staging has been enormously valuable over the
last two decades whilst investigators have attempted to
optimise treatment for Hodgkin's disease. It has been known
for some time that 40-50% of patients with Stage IIIB and
Stage IV Hodgkin's disease could achieve a sustained CR
with four drug chemotherapy schedules such as MOPP (mus-
tine, vincristine, prednisolone and procarbazine), CLVPP
(chlorambucil, vinblastine, prednisolone and procarbazine) or
ABVD (doxorubicin, bleomycin, vincristine and DTIC).
However 50-60% of patients with advanced stage disease do
not do well with these regimens and a number of new
alternating (Bonadonna et al., 1986) or hybrid (Klimo et al.,
1988) combinations have been used. This approach exposes
the patients to an increased number of drugs and their
potential attendant risk of additional early and late side
effects. Such studies have been conducted on patients with
Stage IIIB and IV disease and patients in these staging
groups who were destined to respond to four drug schedules
have been included. The inclusion of these 'good responders'
means that the increased efficacy which has been suggested
for hybrid regimens has been difficult to quantitate.
It is possible to use prognostic factors objectively and add
their weight to classical Ann Arbor staging to produce a
numerical formula to predict those patients of all stages who
are unlikely to be cured by conventional four drug regimens.
Details of the SNLG numerical prognostic index were pub-
lished recently (Proctor et al., 1991). This index was derived
and validated on over 500 cases within the SNLG files. It
was created using data from patients treated with four drug
combinations and is valid for such a Hodgkin's disease
patient population base. In a more recent publication (Proc-
tor et al., 1992) our group has indicated that the index can be
enhanced by an additional factor for bulk. This modified
index is in use to identify patients who require aggressive
therapy from the time of diagnosis of their HD (Proctor et
al., 1992).
Having identified poor risk patients in our population an
aggressive chemotherapeutic regime was formulated for them
which included intensification with autotransplant in first
remission. A continuous hybrid chemotherapy schedule
(PVACE-BOP) was evolved (Proctor et al., 1992) and the
details ofthis are shown in Figure I. The majority ofpatients
in the present study, who underwent ABMT in first or
subsequent remission, received this therapy as either first or
second line treatment prior to high dose chemotherapy with
autotransplant (Table II).
Classical BEAM (BCNU, etoposide, melphalan, cytosine
arabinoside) (Gribben et al., 1989) or CBV (cyclophos-
phamide, carmustine and etoposide) (Armitage et al., 1991;
Reece et al., 1991; Jagannath et al., 1989) ablative
chemotherapy as preconditioning was considered inapprop-
riate as intensification for patients in 1st CR because of the
known toxicity and associated mortality. Our aim in these
patients is to attack the minimal residual disease which may
not required the same degree of chemotherapeutic intensity
developed for treating patients in later stages of disease.
Non-cryopreserved marrow rescue was used as this is
associated with a lack of major procedural toxicity and rapid
engraftment (Carey et al., 1991; Russell et al., 1989; Koppler
et al., 1992). The preconditioning consisted of melphalan and
etoposide (VP16), whose short half-life made cryopreserva-
tion unnecessary. Patients have not experienced any major
toxicity to date.
To conclude, we believe that we have evolved a logical
sequence of treating those patients we consider are at high
risk of dying from progressive HD in the first 4 years from
diagnosis. We therefore:
(1) Identify the poor risk population using the SNLG
prognostic index.
PVACE-BOP
Continuous schedule for aggressive Hodgkin's disease
and relapsed progressive Hodgkin's disease
Day 1 Vincristine 2 mg
Day 1 Etoposide IV 100 mg m-2 x 1
Day 2,3 Etoposide Oral 200 mg m-2
Day 1-14 Procarbazine 100 mg m-2
Day 1-14 Chlorambucil 6 mg m-2
(max 10 mg)
Day 28 = Day 1 of next course
(Proctor etal., 1992)
Figure 1
Day 8 Doxorubicin 25 mgm-2
Day 8 Vinblastine 6 mg m -2
(max 10 mg)
Day 14 Bleomycin 6 mg m-2
(max 10 mg)
Day 21 Bleomycin 6 mg m -2
(max 10 mg)
Day 14-28 Prednisolone 40 mg dailyTREATMENT FOR ADVANCED HODGKIN'S DISEASE 387
(2) Treat the poor risk group with aggressive
chemotherapy from the outset, utilising an eight drug
regime which is given continuously for 12 weeks (PVACE-
BOP) rather than CLVPP.
(3) Utilise high dose intensification with melphalan/VP16
and ABMT, using pilot information on toxicity and
efficacy reported above.
In this way the 40-50% of patients with Stage III or IV
Hodgkin's disease who are destined to be cured of their
disease with a four drug regimen alone, are not overtreated,
and, therefore, are not at increased risk of secondary com-
plications of therapy.
The question of whether patients at risk of early relapse
will benefit from high dose chemotherapy with ABMT fol-
lowing intensive primary therapy still remains. Having pro-
vided this pilot information on the toxicity and efficacy of
ABMT for the SNLG, there is now a prospective randomised
trial in progress to try and answer this question (Proctor et
al., 1992).
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